Ables Iannone Moore & Associates Inc. Purchases New Stake in Pfizer Inc. (NYSE:PFE)

Ables Iannone Moore & Associates Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,353 shares of the biopharmaceutical company’s stock, valued at approximately $39,000.

Other large investors also recently made changes to their positions in the company. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $32,000. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the fourth quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.99 on Tuesday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $39.87. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The company has a 50-day moving average of $27.57 and a two-hundred day moving average of $27.74.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.22%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PFE shares. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.